MedTrace Logo

Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline

NCT02123576 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-05-29

Study results available
· View outcomes & findings →

Summary

Pentoxyfylline therapy in addition to the standard of care of albumin, midodrine and octreotide therapy is superior to the standard of care alone in the treatment of Type I hepatorenal syndrome in the first 14 days of hospitalization.

Conditions

  • Hepatorenal Syndrome

Interventions

DRUG

Pentoxyfylline

DRUG

Placebo

DRUG

AMO Therapy

Albumin, midodrine and octreotide therapy (standard of care for HRS)

Sponsors & Collaborators

  • Patrick Northup, MD

    lead OTHER

Principal Investigators

  • Patrick G Northup, MD MHS · University of Virginia

  • Jonathan G Stine, MD · University of Virginia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02123576 on ClinicalTrials.gov